Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that its President and Chief Executive Officer, David Bupp, will present on Tuesday, February 9, 2010 at 2:30 PM EST, during the 12 th Annual BIO CEO & Investor Conference to be held at the Waldorf Astoria Hotel in New York, NY.

Mr. Bupp will provide a corporate overview, including an update and discussion of the clinical and regulatory status of Neoprobe’s two drug development products, Lymphoseek ® and RIGScan™ CR. A link to a live webcast of Mr. Bupp's presentation will be accessible from the News & Investor Relations page of the Company's website at www.neoprobe.com. An archived version of the webcast will be available for 30 days following the live presentation.

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe ® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek ® and RIGScan™ CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com

Copyright Business Wire 2010